Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) (ABROGATE)

Trial Profile

Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) (ABROGATE)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Aug 2017

At a glance

  • Drugs Abatacept (Primary)
  • Indications Wegener's granulomatosis
  • Focus Therapeutic Use
  • Acronyms ABROGATE
  • Most Recent Events

    • 01 May 2017 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.
    • 01 May 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.
    • 07 May 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top